Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 156 recruiting now early-phase tilt #40 of 28,707 conditions

Opioid Use Disorder: early-phase trial registry

156 of 258 indexed Opioid Use Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #40 of 28,707 conditions by registered trial count.

258 US clinical trials · 156 currently recruiting · #40 of 28,707 conditions by registered trial count

Opioid Use Disorder: 258 US clinical trials tracked, 156 recruiting.

Opioid Use Disorder is the subject of 258 registered US clinical trials on ClinicalTrials.gov, 156 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 19 of these trials.

Enrollment posture brief

Registry condition opioid-use-disorder

OPEN 156 | RECR 60% | LATE 23 | EARLY 59 | RANK #40 | SPON 19

Nearest open-share peer: HIV Prevention (61% recruiting · 33 trials)

Opioid Use Disorder (this)60%Aging47.9%Post Traumatic Stress Disord41.5%Head and Neck Cancer34.2%Melanoma33.1%
Open-enrollment share among volume-matched conditions near Opioid Use Disorder

Opioid Use Disorder lists 156 open slots (60% of 258 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Opioid Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Opioid Use Disorder is recruiting above its size-band peers.

    156 of 258 indexed trials (60.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Opioid Use Disorder trials is spread across many organizations.

    Yale University accounts for 19 of 258 trials (7.4%). 127 distinct sponsors appear on at least one study for this condition label.

  3. Typical Opioid Use Disorder enrolment sits around 103 participants.

    Median target enrolment is 103 among the 258 trials that report a genuine target (sentinel values excluded). 121 of those (46.9%) plan for fewer than 100 participants.

  4. Opioid Use Disorder research is mostly interventional.

    233 interventional and 25 observational studies make up this index (90.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 127Phase 232Phase 312Phase 411

Open and recent trials

258 total, page 5 of 6

ACTIVE NOT RECRUITING NA 10 participants

Pilot Research on Opioid Use Disorder

Theranova, L.L.C.

NCT04244227

COMPLETED NA 973,759 participants

PRimary Care Opioid Use Disorders Treatment (PROUD) Trial

Kaiser Permanente

NCT03407638

COMPLETED 47,502 participants

Natural Language Processing for Screening Opioid Misuse

University of Wisconsin, Madison

NCT05745480

COMPLETED NA 7,950 participants

Coaching Performance Driven Practice Change in the Context of Value Based Purchasing Under New York Medicaid

NYU Langone Health

NCT04632238

COMPLETED NA 7,554 participants

Patient Decision Aid for Opioid Use Disorder

University of California, Los Angeles

NCT03568552

COMPLETED NA 631 participants

PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Opioid-Naive Population

University of Minnesota

NCT04601493

COMPLETED 534 participants

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery

Indivior

NCT03604861

COMPLETED NA 437 participants

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Orexo AB

NCT04948307

COMPLETED Phase 3 380 participants

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Alkermes

NCT02537574

COMPLETED NA 356 participants

Parenting Young Children Study

University of Oregon

NCT05180487

COMPLETED NA 332 participants

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

Karen Derefinko, PhD

NCT04080180

COMPLETED NA 260 participants

Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)

Cambridge Health Alliance

NCT04278586

COMPLETED NA 246 participants

Technology for MAT in Primary Care - Phase 2

Q2i

NCT05017272

COMPLETED NA 230 participants

Treatment of Pregnant Women With OUD

Yale University

NCT04240392

COMPLETED Phase 3 228 participants

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Braeburn Pharmaceuticals

NCT02672111

COMPLETED NA 225 participants

A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail

Friends Research Institute

NCT02334215

COMPLETED Phase 3 208 participants

Open-Label Treatment Extension Study

Indivior

NCT02896296

COMPLETED Phase 2 126 participants

Reducing Pain and Opioid Use With CBD

University of Colorado, Denver

NCT05299944

COMPLETED NA 115 participants

Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0

HealthPartners Institute

NCT04939727

COMPLETED Early Phase 1 104 participants

Enhancing Prospective Thinking in Early Recovery (PARK)

Indiana University

NCT05908097

COMPLETED Phase 4 104 participants

Rapid Initiation of Drug Treatment Engagement

University of Pennsylvania

NCT03908437

COMPLETED NA 88 participants

Substance Use Treatment and Recovery Team (START)

RAND

NCT04314648

COMPLETED NA 81 participants

Transforming Recovery Through Exercise and Community

Butler Hospital

NCT03065049

COMPLETED NA 72 participants

Pilot Test of Patient Decision Aid for Opioid Use Disorder

University of California, Los Angeles

NCT03394261

COMPLETED Phase 2 71 participants

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Laura Fanucchi

NCT04677114

COMPLETED Phase 2 66 participants

Phase II Pharmacokinetics Study of CAM2038

Braeburn Pharmaceuticals

NCT02710526

COMPLETED 65 participants

Harnessing Digital Health to Understand Clinical Trajectories of Opioid Use Disorder

Dartmouth-Hitchcock Medical Center

NCT04535583

COMPLETED NA 61 participants

Evaluating The Efficacy Of A Mind-Body Intervention In Overcoming Opioid Addiction

Ohio State University

NCT03791645

COMPLETED NA 60 participants

BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control

Grace Lim, MD, MS

NCT04365465

COMPLETED NA 55 participants

Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR

HealthPartners Institute

NCT03559179

COMPLETED 53 participants

Emergency Department Outcomes for Patients With Opioid Use Disorder

NYU Langone Health

NCT04289363

COMPLETED 53 participants

Evaluation of Long-term Buprenorphine Plasma Exposure

Indivior

NCT03752528

COMPLETED NA 50 participants

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

University of Connecticut

NCT04531670

COMPLETED NA 48 participants

Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities

New York State Psychiatric Institute

NCT04958798

COMPLETED 46 participants

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Boston Medical Center

NCT03718104

COMPLETED NA 35 participants

Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting

Hunter Holmes Mcguire Veteran Affairs Medical Center

NCT03662529

COMPLETED NA 35 participants

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

Spark Biomedical

NCT04075214

COMPLETED NA 34 participants

Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder

University of Utah

NCT05034276

COMPLETED NA 32 participants

Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders

Southeast Louisiana Veterans Health Care System

NCT03944850

COMPLETED NA 32 participants

Philly NavSTAR Implementation Trial

Friends Research Institute

NCT06634277

COMPLETED Phase 1 30 participants

Cocaine Opioid Oxytocin Option - Limited

University of California, San Francisco

NCT02028533

COMPLETED NA 29 participants

Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.

Brigham and Women's Hospital

NCT03212794

COMPLETED NA 28 participants

Effect of Music on Cue Reactivity for Patients With Opioid Use Disorder

Brigham and Women's Hospital

NCT06948890

COMPLETED NA 27 participants

MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence

Dartmouth-Hitchcock Medical Center

NCT02778282

COMPLETED Phase 1 24 participants

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

Astellas Pharma Global Development

NCT04448561

COMPLETED NA 24 participants

AWAITS: A Web-based E-health Application for Active Illicit Opioid Users

University of Cincinnati

NCT03402672

COMPLETED NA 24 participants

Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings

University of Nevada, Las Vegas

NCT05074524

COMPLETED Early Phase 1 20 participants

Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Friends Research Institute

NCT04308694

COMPLETED NA 19 participants

Tai Chi Easy for Opioid Use Disorder, Anxiety, and Chronic Pain

Asana Recovery

NCT05850533

COMPLETED 19 participants

mHealth for Patient Self-Management of Opioid Use Disorder

Biomedical Development Corporation

NCT03633929

← Previous Page 5 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 27
Phase 2 32
Phase 3 12
Phase 4 11

Named interventions

Most-linked intervention names on Opioid Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
13 trials
Buprenorphine Drug
5 trials
Psilocybin Drug
4 trials
Usual Care Behavioral
4 trials
Lofexidine Drug
3 trials
Contingency Management Behavioral
3 trials
Treatment as Usual (TAU) Behavioral
3 trials
Methadone Drug
3 trials

US sites by state

Facility locations filed on Opioid Use Disorder trials. A trial with sites in several states counts in each.

Pennsylvania 40 trials
Massachusetts 30 trials
New York 29 trials
California 29 trials
Maryland 26 trials
Connecticut 20 trials
Ohio 15 trials
New Jersey 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Opioid Use Disorder page

258 registered trials, 156 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 156 Opioid Use Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Yale University sponsors the most Opioid Use Disorder trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Opioid Use Disorder condition card totals 258 registered trials; most-linked intervention Placebo; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.